Business · 05/02/2002Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for REFACTO Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for REFACTO, a human biological product, as required by law, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce, for patent extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →